TBAJ-876 results from brilliant med chem (done, I think, in group of Bill Denny @aucklanduni). They drove BDQ's cLogP from 7.2 to 5.2µM, hERG inhibition IC50 from 1.6 to >30µM, and improved MIC90 from 0.04 to 0.004µg/mL.
Our structure shows the improved binding to ATP synthase.

SQ31f, a novel squaramide compound, stops ATP synthase by exploiting a previously unknown binding pocket that our collaborators and others can now try to target. Interestingly, BDQ, TBAJ-876, and SQ31f all target the enzyme in approximately the same conformation.

Using multiple assays, Gautier investigated the mysterious proton motive force uncoupling by mycobacterial ATP synthase inhibitors. These results may give insight into why some inhibitors (eg diarylquinolines) are bactericidal while others (eg squaramides) are bacteriostatic.